| 1 |
33176060 | Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity. | 2021 Feb |
1 |
| 2 |
33234593 | A quantitative method to detect non-antithrombin-binding 3-O-sulfated units in heparan sulfate. | 2021 Jan-Jun |
1 |
| 3 |
33794550 | Effect of Heparanase and Heparan Sulfate Chains in Hemostasis. | 2021 Apr |
1 |
| 4 |
33924175 | Antithrombin and Its Role in Host Defense and Inflammation. | 2021 Apr 20 |
1 |
| 5 |
34743814 | SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate. | 2021 Dec 15 |
1 |
| 6 |
32002903 | 3D Cell-Culture Models for the Assessment of Anticoagulant and Anti-Inflammatory Properties of Endothelial Cells. | 2020 |
1 |
| 7 |
33146178 | Visualizing antithrombin-binding 3-O-sulfated heparan sulfate motifs on cell surfaces. | 2020 Nov 19 |
2 |
| 8 |
29173042 | Antithrombin conformational modulation by D-myo-inositol 3,4,5,6-tetrakisphosphate (TMI), a novel scaffold for the development of antithrombotic agents. | 2018 Nov |
1 |
| 9 |
29999301 | Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin. | 2018 Aug 14 |
1 |
| 10 |
25483839 | Dynamic properties of the native free antithrombin from molecular dynamics simulations: computational evidence for solvent- exposed Arg393 side chain. | 2015 Sep |
1 |
| 11 |
25600805 | Heparin cofactor II is degraded by heparan sulfate and dextran sulfate. | 2015 Feb 20 |
1 |
| 12 |
25851619 | Selective disruption of heparin and antithrombin-mediated regulation of human factor IX. | 2015 Jun |
1 |
| 13 |
25921251 | High-resolution probing heparan sulfate-antithrombin interaction on a single endothelial cell surface: single-molecule AFM studies. | 2015 May 28 |
5 |
| 14 |
24678194 | Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition. | 2014 Jan |
1 |
| 15 |
23083208 | An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence. | 2013 Jan 15 |
1 |
| 16 |
24121110 | Sequence, phylogenetic and variant analyses of antithrombin III. | 2013 Nov 1 |
1 |
| 17 |
23152789 | On the specificity of heparin/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different. | 2012 |
1 |
| 18 |
20685328 | Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. | 2010 Nov |
1 |
| 19 |
19185514 | Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif. | 2009 Apr |
1 |
| 20 |
18278163 | [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. | 2008 Feb |
1 |
| 21 |
18669628 | Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity. | 2008 Oct 17 |
1 |
| 22 |
18761723 | Heparan sulfates from arteries and veins differ in their antithrombin-mediated anticoagulant activity. | 2008 Nov |
1 |
| 23 |
19035835 | Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. | 2008 Dec 23 |
1 |
| 24 |
16394262 | Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. | 2006 Jan |
1 |
| 25 |
17040907 | Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. | 2006 Dec 8 |
5 |
| 26 |
15652173 | Structural characterization of human liver heparan sulfate. | 2005 Jan 18 |
1 |
| 27 |
15878740 | Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. | 2005 Apr 15 |
2 |
| 28 |
15968398 | Expression and function of syndecan-4 in human platelets. | 2005 Jun |
2 |
| 29 |
16260789 | Enzymatic redesigning of biologically active heparan sulfate. | 2005 Dec 30 |
1 |
| 30 |
15060080 | Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. | 2004 Jun 11 |
2 |
| 31 |
12581643 | Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. | 2003 Feb 21 |
1 |
| 32 |
12591924 | Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. | 2003 Apr 18 |
1 |
| 33 |
12886459 | Glycosaminoglycans affect the interaction of human plasma kallikrein with plasminogen, factor XII and inhibitors. | 2003 Aug |
1 |
| 34 |
14575696 | Platelet factor 4 neutralizes heparan sulfate-enhanced antithrombin inactivation of factor Xa by preventing interaction(s) of enzyme with polysaccharide. | 2003 Nov 7 |
1 |
| 35 |
12168569 | The anti-inflammatory actions of antithrombin--a review. | 2002 |
1 |
| 36 |
12244479 | Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution. | 2002 Aug |
1 |
| 37 |
11522012 | High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity--implications for cancer related thromboembolism and heparin therapy. | 2001 Aug |
1 |
| 38 |
10722716 | The effect of a reducing-end extension on pentasaccharide binding by antithrombin. | 2000 Mar 24 |
1 |
| 39 |
10810875 | [Endothelial cells and coagulation abnormalities]. | 2000 Apr |
1 |
| 40 |
11006120 | Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. | 2000 Sep 16 |
4 |
| 41 |
10026234 | Localization and characterization of antithrombin in human kidneys. | 1999 Mar |
1 |
| 42 |
10065896 | On the control of the plasma contact activation system on human endothelium: comparisons with heparin surface. | 1999 Jan 1 |
4 |
| 43 |
10914239 | [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia]. | 1999 Mar 1 |
1 |
| 44 |
11212344 | Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. | 1999 Nov 30 |
1 |
| 45 |
9916505 | [Autoantibodies to heparin polysaccharides bind to vascular endothelial cells]. | 1998 Dec |
2 |
| 46 |
9213829 | [Effectiveness and tolerability of heparan sulfate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide]. | 1997 Apr |
1 |
| 47 |
9251237 | Heparan sulphate. | 1997 May |
1 |
| 48 |
9374919 | The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. | 1997 Oct |
1 |
| 49 |
9395268 | Endothelial-derived nitric oxide preserves anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. | 1997 Nov |
1 |
| 50 |
8689765 | Endothelial cell activation in cutaneous vasculitis. | 1996 Jan |
2 |